Immutep Limited announced appointment of four new members to the Company's Clinical Advisory Board (CAB). The new appointments to Immutep's CAB are: Scott Antonia, M.D., Ph.D. is recognised as a global leader in the development of immunotherapy for lung cancer. He currently serves as the director of the Duke Cancer Institute (DCI) Center for Cancer Immunotherapy and is a member of the Thoracic Oncology disease group as Professor of Medical Oncology.

Leisha A Emens, M.D., Ph.D. is a Professor of Medicine at the UPMC Hillman Cancer Center. She is a medical oncologist focused on breast cancer and is internationally recognised for her work in breast cancer immunotherapy. She developed and tested a vaccine for breast cancer patients, and more recently has played a key role in the development of the anti-PD-L1 agent atezolizumab for triple negative breast cancer and HER2+ breast cancer.

Martin Forster, M.D., Ph.D., is an associate professor at University College London (UCL) and consultant medical oncologist at University College Hospital. Professor Forster is a core member of the lung and head and neck cancer teams and runs a research-based practice, being principal investigator or chief investigator for over 50 early and late-phase clinical trials, from first-in- human to registration Phase III trials. Hans Wildiers, M.D., Ph.D., is a dedicated breast cancer researcher and medical oncologist.

He has been a staff member at the Department of Medical Oncology at the University Hospital Leuven, Belgium, since 2004.